In a cohort study by Ceccato et al., 102 out of the 582 patients studied had aggressive pituitary tumors defined based on their radiological features (tumor size, local invasion), pathological reports (MIB-1 > 3%, p53 immunoreactivity, increased mitotic activity), and response to treatment. This evidence concerns the gene TP53 and pituitary tumor.